These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 34469563)

  • 41. Pneumococcal nasopharyngeal carriage in children <5 years of age visiting the pediatric emergency room in relation to PCV7 and PCV13 introduction in southern Israel.
    Ben-Shimol S; Givon-Lavi N; Greenberg D; Dagan R
    Hum Vaccin Immunother; 2016; 12(2):268-76. PubMed ID: 26430921
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term impact of pneumococcal conjugate vaccines for children on adult pneumococcal pneumonia in Japan: Two multicenter observational studies from 2011 to 2020.
    Maeda H; Gopal Dhoubhadel B; Sando E; Suzuki M; Furumoto A; Asoh N; Yaegashi M; Aoshima M; Ishida M; Hamaguchi S; Otsuka Y; Morimoto K
    Vaccine; 2022 Sep; 40(37):5504-5512. PubMed ID: 35963821
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pediatric parapneumonic effusion before and after national pneumococcal vaccination programs in Taiwan.
    Sim JY; Chang LY; Chang TH; Chen JM; Lee PI; Huang LM; Lu CY
    J Formos Med Assoc; 2020 Nov; 119(11):1608-1618. PubMed ID: 32747171
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England.
    van Hoek AJ; Sheppard CL; Andrews NJ; Waight PA; Slack MP; Harrison TG; Ladhani SN; Miller E
    Vaccine; 2014 Jul; 32(34):4349-55. PubMed ID: 24657717
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serotype distribution of Streptococcus pneumoniae and potential impact of pneumococcal conjugate vaccines in China: A systematic review and meta-analysis.
    Chen K; Zhang X; Shan W; Zhao G; Zhang T
    Hum Vaccin Immunother; 2018 Jun; 14(6):1453-1463. PubMed ID: 29451838
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Five winters of pneumococcal serotype replacement in UK carriage following PCV introduction.
    Gladstone RA; Jefferies JM; Tocheva AS; Beard KR; Garley D; Chong WW; Bentley SD; Faust SN; Clarke SC
    Vaccine; 2015 Apr; 33(17):2015-21. PubMed ID: 25776920
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP; Whitney CG;
    MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
    Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T
    Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Decreasing incidence and changes in serotype distribution of invasive pneumococcal disease in persons aged under 18 years since introduction of 10-valent and 13-valent conjugate vaccines in Portugal, July 2008 to June 2012.
    Aguiar SI; Brito MJ; Horacio AN; Lopes JP; Ramirez M; Melo-Cristino J; ;
    Euro Surveill; 2014 Mar; 19(12):20750. PubMed ID: 24698140
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Early Streptococcus pneumoniae serotype changes in Utah adults after the introduction of PCV13 in children.
    Kendall BA; Dascomb KK; Mehta RR; Stockmann C; Mason EO; Ampofo K; Pavia AT; Byington CL
    Vaccine; 2016 Jan; 34(4):474-478. PubMed ID: 26706276
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A multicenter study on the epidemiology of complicated parapneumonic effusion in the era of currently available pneumococcal conjugate vaccines.
    Papachristidou S; Lapea V; Charisi M; Kourkouni E; Kousi D; Xirogianni A; Dedousi O; Papaconstadopoulos I; Eleftheriou E; Krepis P; Pasparaki S; Pantalos G; Doudoulakakis A; Bozavoutoglou E; Daskalaki M; Kostaridou-Nikolopoulou S; Tzanakaki G; Spoulou V; Tsolia M
    Vaccine; 2023 Oct; 41(45):6727-6733. PubMed ID: 37805358
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis, Burkina Faso, 2016-2017.
    Soeters HM; Kambiré D; Sawadogo G; Ouédraogo-Traoré R; Bicaba B; Medah I; Sangaré L; Ouédraogo AS; Ouangraoua S; Yaméogo I; Congo-Ouédraogo M; Ky Ba A; Aké F; Srinivasan V; Novak RT; McGee L; Whitney CG; Van Beneden C
    J Infect Dis; 2019 Oct; 220(220 Suppl 4):S253-S262. PubMed ID: 31671444
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children.
    Angoulvant F; Levy C; Grimprel E; Varon E; Lorrot M; Biscardi S; Minodier P; Dommergues MA; Hees L; Gillet Y; Craiu I; Zenkhri F; Dubos F; Guen CG; Launay E; Martinot A; Cohen R
    Clin Infect Dis; 2014 Apr; 58(7):918-24. PubMed ID: 24532543
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case-control study.
    Cohen C; von Mollendorf C; de Gouveia L; Lengana S; Meiring S; Quan V; Nguweneza A; Moore DP; Reubenson G; Moshe M; Madhi SA; Eley B; Hallbauer U; Finlayson H; Varughese S; O'Brien KL; Zell ER; Klugman KP; Whitney CG; von Gottberg A;
    Lancet Glob Health; 2017 Mar; 5(3):e359-e369. PubMed ID: 28139443
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Change in Pneumococcus Serotypes but not Mortality or Morbidity in Pre- and Post-13-Valent Polysaccharide Conjugate Vaccine Era: Epidemiology in a Pediatric Intensive Care Unit over 10 Years.
    Hon KL; Chan KH; Ko PL; Cheung MHY; Tsang KYC; Chan LCN; Chan RWY; Leung TF; Ip M
    J Trop Pediatr; 2018 Oct; 64(5):403-408. PubMed ID: 29126217
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nasopharyngeal pneumococcal carriage in healthy Turkish children after 13-valent conjugated pneumococcal vaccine implementation in the national immunization program.
    Kanık Yüksek S; Tezer H; Gülhan B; Özkaya Parlakay A; Güldemir D; Coskun-Ari FF; Bedir Demirdağ T; Kara Uzun A; Kızılgün M; Solmaz S; Kılıç S; Yalınay Çırak M; Baran Aksakal FN
    J Infect Public Health; 2020 Feb; 13(2):266-274. PubMed ID: 31818710
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adult indication 13-valent pneumococcal conjugate vaccine clinical development overview: formulation, safety, immunogenicity (dosing and sequence), coadministration, and efficacy.
    Fletcher MA; Schmoele-Thoma B; Vojicic J; Daigle D; Paradiso PR; Del Carmen Morales G
    Expert Rev Vaccines; 2024; 23(1):944-957. PubMed ID: 39279631
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
    Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evolving role of 13-valent pneumococcal conjugate vaccine in clinical practice.
    Azzari C; Martinón-Torres F; Schmitt HJ; Dagan R
    Pediatr Infect Dis J; 2014 Aug; 33(8):858-64. PubMed ID: 24618937
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The changing epidemiology of invasive pneumococcal disease after PCV13 vaccination in a country with intermediate vaccination coverage.
    Ciruela P; Izquierdo C; Broner S; Muñoz-Almagro C; Hernández S; Ardanuy C; Pallarés R; Domínguez A; Jané M;
    Vaccine; 2018 Nov; 36(50):7744-7752. PubMed ID: 30473132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.